Last reviewed · How we verify
Mometasone Furoate Nasal Irrigation
Mometasone furoate is a topical corticosteroid that reduces inflammation in the nasal passages when delivered via irrigation.
Mometasone furoate is a topical corticosteroid that reduces inflammation in the nasal passages when delivered via irrigation. Used for Chronic rhinosinusitis, Allergic rhinitis, Post-operative sinus care.
At a glance
| Generic name | Mometasone Furoate Nasal Irrigation |
|---|---|
| Sponsor | Washington University School of Medicine |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Otolaryngology / Allergy / Immunology |
| Phase | FDA-approved |
Mechanism of action
Mometasone furoate binds to glucocorticoid receptors in nasal tissue, suppressing inflammatory cytokine production and reducing edema, mucus production, and allergic/inflammatory responses. When administered as a nasal irrigation, it delivers the active corticosteroid directly to affected nasal and sinus mucosa, providing localized anti-inflammatory effects with minimal systemic absorption.
Approved indications
- Chronic rhinosinusitis
- Allergic rhinitis
- Post-operative sinus care
Common side effects
- Epistaxis (nosebleed)
- Nasal irritation
- Headache
- Pharyngeal irritation
Key clinical trials
- Effectiveness of Mometasone Nasal Irrigation for Chronic Rhinosinusitis (PHASE4)
- 3D Printing to Improve Nasal Irrigation Outcome (NA)
- Potential for Cortisol Suppression With the Use of High Volume Nasal Mometasone Irrigations in Varying Dosages. (PHASE1)
- Azelastine Allergen Chamber - Onset of Action Study (PHASE2)
- Efficacy of Azelastine and Mometasone Irrigation in Comparison to Nasal Sprays in Patients With Chronic Rhinitis (PHASE4)
- Mometasone vs Budesonide in CRS With Polyposis (PHASE3)
- Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays (PHASE1)
- A Study to Compare the Efficacy of QAV680 Against Placebo in Treating Seasonal Allergic Rhinitis in an Environmental Exposure Chamber (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: